Levamisole
- Generic Name
- Levamisole
- Drug Type
- Small Molecule
- Chemical Formula
- C11H12N2S
- CAS Number
- 14769-73-4
- Unique Ingredient Identifier
- 2880D3468G
- Background
Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by Janssen and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis.
Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. This drug has also been used in combination with other drugs for the treatment of various cancers.
Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranulocytosis. Interestingly, levamisole has been found as an adulterant in cocaine and can lead to a variety of adverse effects in individuals using this drug.
- Indication
For adjuvant treatment in combination with fluorouracil after surgical resection in patients with Dukes' stage C colon cancer. Also used to treat malignant melanoma and head/neck cancer.
- Associated Conditions
- Adenocarcinoma of Colon, Ancylostoma duodenale infection, Ascaris lumbricoides infection, Colorectal Carcinoma (CRC), Enterobius vermicularis infection, Necatoriasis due to necator americanus, Strongyloides Stercoralis Infection, Trichuris Infection
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
- Conditions
- Loiasis
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
- Target Recruit Count
- 99
- Registration Number
- NCT06252961
- Locations
- 🇨🇬
Supervisor, Sibiti, Komono, Congo
🇨🇬General Supervisor, Sibiti, Mokassi, Congo
The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children
- Conditions
- Nephrotic Syndrome in Children
- Interventions
- Drug: Huaiqihuang Granule placebo
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Jianhua Zhou
- Target Recruit Count
- 402
- Registration Number
- NCT05772871
- Locations
- 🇨🇳
Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Anhui Children's Hospital, Hefei, Anhui, China
🇨🇳Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial
- Conditions
- Respiratory Tract Infections
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 60
- Registration Number
- NCT04383717
Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 100
- Registration Number
- NCT04360122
- Locations
- 🇪🇬
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: Lopinavir/Ritonavir + hydoxychloroquine
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Fasa University of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04331470
- Locations
- 🇮🇷
Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of
Novel Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- HCC
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 300
- Registration Number
- NCT03950518
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Treatment of Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- ICC
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 152
- Registration Number
- NCT03940378
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
- Conditions
- Aplastic Anemia
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Shengyun Lin
- Target Recruit Count
- 248
- Registration Number
- NCT03218657
- Locations
- 🇨🇳
Zhejiang Province Traditional Chinese Medical Hospital, Hangzhou, Zhejiang, China
Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children
- Conditions
- First Manifestation of Steroid Sensitive Nephrotic Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 86
- Registration Number
- NCT02818738
- Locations
- 🇫🇷
Hôpital Robert Debré, Paris, France
Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.
- Conditions
- AnemiaAnemia, HemolyticAnemia, Hemolytic, AutoimmuneHemolysisHematologic DiseasesAutoimmune DiseasesImmune System DiseasesPathologic Processes
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2012-04-19
- Target Recruit Count
- 100
- Registration Number
- NCT01579110
- Locations
- 🇨🇳
Blood Diseases Hospital Chinese Academy of Medical Sciences, TianJin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.